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Abstract. The current study reports the clinical features and treatment outcome of 67 patients with 
acute promyelocytic leukemia (APL) treated at National Cancer Institute (NCI
from January 2007 to January 2011. The median age at presentation was 29
the most common presenting symptom (79%). Most patients had an intermediate risk Sanz score 
(49%) and 34% had a high risk score. The median follow
patients were treated for induction with the simul
(ATRA) and an anthracycline. The original AIDA treatment protocol was modified due to resource 
limitations at the NCI-Cairo by replacing of idarubicin with daunorubicin or doxorubicin in most 
of  the  cases  and  the  inclusion  of  cytarabine  during  the  consolidation  phase  only  in  pediatric 
patients. All patients who achieved molecular complete remission after consolidation received two
year  maintenance  treatment  with  low  dose  chemotherapy  composed  of  6  mercaptopu
methotrexate and intermittent ATRA courses. Five patients died before treatment initiation due to 
bleeding,  three  died  during  induction  chemotherapy  due  to  infectious  complications  (n=2)  and 
bleeding  (n=1)  and  one  patient  died  during  consolidation  th
therapeutic complications  during  the induction  phase were febrile  neutropenia  (42%),  bleeding 
(18%)  and  differentiation  syndrome  (11%).  All  patients  achieved  molecular  CR  at  end  of 
consolidation therapy at a median time of 
at  13  and  24  months,  respectively.  Adapting  standard  AIDA  treatment  protocols  to  limited 
resources by reducing dose-intensity during consolidation, using ATRA in the consolidation phase 
and alternative anthracyclin (doxorubicin) may be a valid treatment option for APL in developing 
countries. In spite of the increased incidence of high and intermediate risk disease in our cohort, we 
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The current study reports the clinical features and treatment outcome of 67 patients with 
acute promyelocytic leukemia (APL) treated at National Cancer Institute (NCI
from January 2007 to January 2011. The median age at presentation was 29
the most common presenting symptom (79%). Most patients had an intermediate risk Sanz score 
(49%) and 34% had a high risk score. The median follow-up time was 36 months. All evaluable 
patients were treated for induction with the simultaneous administration of all
(ATRA) and an anthracycline. The original AIDA treatment protocol was modified due to resource 
Cairo by replacing of idarubicin with daunorubicin or doxorubicin in most 
nd  the  inclusion  of  cytarabine  during  the  consolidation  phase  only  in  pediatric 
patients. All patients who achieved molecular complete remission after consolidation received two
year  maintenance  treatment  with  low  dose  chemotherapy  composed  of  6  mercaptopu
methotrexate and intermittent ATRA courses. Five patients died before treatment initiation due to 
bleeding,  three  died  during  induction  chemotherapy  due  to  infectious  complications  (n=2)  and 
bleeding  (n=1)  and  one  patient  died  during  consolidation  therapy  due  to  infection.  The  main 
therapeutic complications  during  the induction  phase were febrile  neutropenia  (42%),  bleeding 
(18%)  and  differentiation  syndrome  (11%).  All  patients  achieved  molecular  CR  at  end  of 
consolidation therapy at a median time of 100 days. The 3-year OS was 89%. Two patients relapsed 
at  13  and  24  months,  respectively.  Adapting  standard  AIDA  treatment  protocols  to  limited 
intensity during consolidation, using ATRA in the consolidation phase 
anthracyclin (doxorubicin) may be a valid treatment option for APL in developing 
countries. In spite of the increased incidence of high and intermediate risk disease in our cohort, we 
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The current study reports the clinical features and treatment outcome of 67 patients with 
acute promyelocytic leukemia (APL) treated at National Cancer Institute (NCI-Cairo), in Egypt 
from January 2007 to January 2011. The median age at presentation was 29 years.  Bleeding was 
the most common presenting symptom (79%). Most patients had an intermediate risk Sanz score 
up time was 36 months. All evaluable 
taneous administration of all-trans retinoic acid 
(ATRA) and an anthracycline. The original AIDA treatment protocol was modified due to resource 
Cairo by replacing of idarubicin with daunorubicin or doxorubicin in most 
nd  the  inclusion  of  cytarabine  during  the  consolidation  phase  only  in  pediatric 
patients. All patients who achieved molecular complete remission after consolidation received two-
year  maintenance  treatment  with  low  dose  chemotherapy  composed  of  6  mercaptopurine, 
methotrexate and intermittent ATRA courses. Five patients died before treatment initiation due to 
bleeding,  three  died  during  induction  chemotherapy  due  to  infectious  complications  (n=2)  and 
erapy  due  to  infection.  The  main 
therapeutic complications  during  the induction  phase were febrile  neutropenia  (42%),  bleeding 
(18%)  and  differentiation  syndrome  (11%).  All  patients  achieved  molecular  CR  at  end  of 
year OS was 89%. Two patients relapsed 
at  13  and  24  months,  respectively.  Adapting  standard  AIDA  treatment  protocols  to  limited 
intensity during consolidation, using ATRA in the consolidation phase 
anthracyclin (doxorubicin) may be a valid treatment option for APL in developing 
countries. In spite of the increased incidence of high and intermediate risk disease in our cohort, we Mediterr J Hematol Infect Dis 2011; 3; Open Journal System 
reported an acceptable CR rate, toxicity and OS. 
Introduction. Acute promyelocytic leukemia (APL) is 
a  distinct  subtype  of  acute  myeloid  leukemia 
characterized by its morphology, t(15;17) translocation 
leading to PML-RARa fusion gene. APL represents 5-
20 % of AML patients.
1,2 In Egypt, leukemia comprises 
10%  of  all  malignancies  with  AML  representing 
16.9%.
3 The  National  Cancer  Institute  is  the  1
st and 
largest comprehensive cancer center in the Egypt and 
the Middle East. Annually around 19,500 new cancer 
patients present to the NCI. Leukemia represents 7% of 
all  malignancies.
4 With  the  introduction  of  all-trans 
retinoic  acid  (ATRA;  tretinoin)  in  the treatment 
armamentarium of APL, 90% of patients can achieve 
complete  remission  and  about  70%  of  them  are 
potentially cured.
5-8
The NCI standard of care for the treatment of APL 
patients is based on the simultaneous administration of 
ATRA and an anthracycline based chemotherapy given 
both  at  induction  and  consolidation  (AIDA-like 
protocol).
5-9 Two years of maintenance treatment are 
offered for all patients achieving molecular complete 
remission  at  the  end  of  consolidation.  As  for  the 
pediatric  patients  cytarabine  (Ara-C)  is  added  to  the 
consolidation  treatment.  However,  two  major  health 
care  problems  exist  in  Egypt:  these  are  limited 
resources  and  lack  of  non-governmental 
reimbursement  of  expensive  drugs  such  as  arsenic 
trioxide for salvage therapy.  Hence at the NCI-Cairo, 
regimens are  adopted  and  modified according to  the 
highest CR, EFS, and the least toxicity profile together 
with the highest possible cost effectiveness. Therefore, 
APL treatment protocol was also modified according to 
the available resources mainly by the replacement of 
Idarubicin  with  Doxorubicin  and  reducing  dose 
intensity in consolidation as detailed in methods below. 
Here, we report the clinical features and the treatment 
outcome of APL patients admitted to our center from 
January 2007- to January 2011 and treated according to 
NCI-Cairo APL protocol.   
Patients  and  methods.  Patient  selection:  Patients 
diagnosed  with  APL  genetically  confirmed  by  the 
presence of t(15;17) and/or of the PML/RARA fusion 
by  RT-PCR  were  enrolled.  Age,  gender,  comorbid 
conditions at presentation, initial WBC, platelet count, 
Sanz score and FLT3 internal tandem duplication were 
analyzed.  Induction  treatment  for  adult  (>18  yrs) 
patients  consisted  of  3  doses  of  intravenous 
doxorubicin  60mg/m
2 or  idarubicin  12mg/m
2 D1-3 
combined  with  All  Trans  Retinoic  acid  (ATRA) 
45mg/m
2 in  2  divided  doses  till  morphological 
complete remission or for a maximum of 45 days. At 
the end of induction therapy the bone marrow for all 
patients  was  assessed  for  morphologic  CR  after 
complete  recovery  of  their  blood  counts.  Patients 
achieving  CR  received  consolidation  therapy 
consisting  of  2  cycles  of  3  doses  of  doxorubicin 
60mg/m
2 or idarubicin 12mg/m
2 D1-3 in combination 
with ATRA 45mg/m
2 for 15 days. Patients who did not 
achieve morphologic CR received 3 further cycles of 
the same induction regimen.
At  end  of  consolidation  therapy,  molecular  CR 
(CRm)  was  assessed  initially  by  FISH  and 
subsequently  confirmed  by  RT–PCR  for  PML-RARA
transcript.
10 All patients achieving molecular CR were 
offered  a  2-year  maintenance  treatment  with  6 
mercaptupurine  60mg/m
2/d,  methotrexate  15mg/m2 
IM/weekly  and  ATRA  45mg/m2  D1-14  every  3 
months.
For  pediatric  patients  (<18  yrs),  the  ATRA  dose 
was reduced to 25mg/m
2 and was given for a max of 60 
days during induction in combination with Idarubicin 
12mg/m2 at D3, 5, 7 for standard risk patients and at 
D1, 3, 5 for high risk patients.  
Consolidation  therapy  consisted  of  two  cycles  as 
follows: Consolidation I consisted of ATRA 25mg/m
2
for 14 days plus high dose Ara-C (1gm /m
2 dose/12hrs 
D1-3)  and  mitoxantrone  (10mg/m
2 D4,5).  
Consolidation II consisted of ATRA 25mg/m
2 for 14 
days  in  combination  with  Idarubicin  5mg/m
2 dose 
D1,3,5.  Intrathecal  Ara-C  was  given  once  at  each 
consolidation cycle. High risk patients or patients not 
achieving  molecular  CR  received  a  3
rd cycle  of  the 
same regimen given at consolidation I. 
Maintenance  treatment  for  pediatric  APL  patients 
consisted of ATRA 25mg/m2 D1-14, 6 mercaptopurine 
50mg/m2/d  and  methotrexate  25mg/m
2 weekly for  2 
years. Intrathecal Ara-C was given every 3 months for 
1 year to all patients.
Supportive therapy was given to all patients during 
the  entire  duration  of  induction.  Platelets  and  fresh 
frozen  plasma  were  transfused  to  maintain  platelets 
count > 50 x 10
9/l and fibrinogen >150 mg/dl. Packed 
red cell concentrates were given to maintain Hb level > 
8  gr/dl.  During  induction  therapy,  prednisone  at  the 
dose of 0.5 mg/kg/d was administered to prevent APL 
differentiation syndrome in patients with WBC ≥10x 
10
9/L.  Once  APL  differentiation  syndrome  was 
suspected,  ATRA  treatment  was  temporarily 
discontinued and dexamethasone given i.v. at 10 mg/12 
hrs for 4 days or until disappearance of symptoms and 
signs of the syndrome. 
Outcome  definitions  and  statistical  analysis: 
Hematologic CR (HCR) was defined as the Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Table 1. Patient characteristics.
reconstitution of normal marrow cellularity with less 
than  5%  leukemic  promyelocytes,  together  with  PB 
cell counts of polymorphonuclear leukocytes (PMN) > 
1,500/μL  and  platelets  >100,000/μL.  Molecular 
remission (CRm) was defined as the disappearance, on 
an ethidium bromide-stained electrophoresis gel, of the 
specific  PML/RARA amplification  band  identified  at 
diagnosis.  Overall  survival  (OS)  was  defined  as  the 
time from the diagnosis to death from any cause. For 
the statistical analysis, (SPSS 15.0 software, USA) was 
used. Numerical data were described in terms of means 
and  medians  for  central  tendency  and  standard 
deviation  and  range,  minimum  and  maximum  for 
dispersion. Overall survival was determined using the 
Kaplan-Meier product limit method. 
Results.  Baseline  clinical  and  laboratory 
characteristics: From January 2007 to January 2011, 
67 genetically confirmed APL patients were diagnosed 
at the Medical Oncology Department, National Cancer 
Institute Cairo University, Egypt.
The  baseline  characteristics  of  these  patients  are 
summarized in Table 1. The median age was 29 years 
(range, 3-72), 53 patients were 18 years of age or older 
and 14 patients were younger than 18 years. There was 
a slight male predominance (53%). Patients presenting 
with APL related complications were 80% of the total.
These were mainly in the form of bleeding (79%) and 
febrile  neutropenia  (5%)  while  positive  hepatitis  C 
virus  as  a  comorbid  condition  was  seen  in  1.5%  of 
patients. Blood and platelet transfusion as supportive 
therapy  were  given  to  all  patients  as  indicated.  
According to Sanz score (5), patients were mainly in 
the intermediate risk (49%) and 32% were of high risk. 
FLT3-ITD mutation was assessed in only 14 patients of 
whom 3 were positive.
Treatment  outcome: Only  62  patients  received 
induction therapy. Of them 51 received the adult APL 
protocol and 11 received the pediatric APL protocol as 
described  above.  The  remaining  5  patients  were 
considered as failures due to early death within three 
days of admission and before induction. All of them 
died  due  to  intracranial  hemorrhage.  Complications 
during induction were documented in 41 patients(66%) 
and consisted febrile neutropenia 42%, bleeding 18%, 
differentiation  syndrome  11%,  and  heart  failure 
N % N %
Total 67 Total 67
Median age (range)      Bone Marrow Cellularity
    ≥18years                    33   (18-72) 53     Hypocellular  26 39
   <18 years:                   10.4 (3-16) 14     Hypercellular  17 25
Sex     Normal cellular 24 36
    Male 36 53 FLT3-ITD (only in 14 patients)
    Female 28 41     Wild  11 79
Clinical conditions at Diagnosis      FLT3-ITD mutation 3 21
    Bleeding  53 79 Induction Treatment                              n=62
    Febrile neutropenia 5 7 Doxorubicin or Idarubicin + ATRA 51 82
    HCV 1 1.5 Pediatric protocol 11 18
Transfusion Induction Complications
     Blood Transfusion 66 98     Bleeding  11 18
     Platelet transfusion  63 94     Febrile neutropenia 26 42
Organomegaly      Differentiation syndrome  7 11
    Hepatomegaly  6 9     Heart failure  1 1.6
    Splenomegaly 7 10     Death during induction 3 4.47
WBC count  Consolidation regimen                           n=59
    WBC≥10 (x 10
9/L) 23 34     Doxorubicin + ATRA 47 80
    WBC<10 (x 10
9/L) 44 66     Pediatric protocol 12 20
Platelet Count Consolidation Complication
    ≥40 (x 10
9/L) 16 24     Febrile neutropenia 9 15
    <40 (x 10
9/L) 51 76     Death  1 1.49
Sans Risk category Maintenance treatment                          n=58
    Low  risk  11 16 Median survival mo 19.23 
    Intermediate  risk 33 49     (95% CI) (16.33-23.75)
    High Risk 23 34Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Figure 1: Overall survival of APL patients.
in 1.6%. Induction mortality was recorded in 3 patients 
(4.8%)  and  were  due  to  infection  in  2  patients  and 
bleeding in one). 
Fifty nine patients received consolidation treatment 
as  planned.  One  patient  died  during  consolidation 
therapy due to sepsis. At the end of consolidation, all 
the 58 evaluable patients achieved complete molecular 
remission.  The  median  time  to  complete  molecular 
remission was 100 days. The 3-year OS was 88% and 
two patients relapsed at 13 and 24 months from CR. 
They both received the same induction therapy and are 
alive in CR.
Discussion. Our results reveal the various challenges 
faced in countries with limited resources, like Egypt, in 
the  treatment  of  APL.  At  the  NCI-Cairo  adult  APL 
patients are treated with a modified PETHEMA LPA99
regimen  with  simultaneous  administration  of 
doxorubicin  and  ATRA  in  the  induction  and 
consolidation  phases.
9 Doxorubicin  is  used  as  a 
replacement  for  Idarubicin,  because  it  is  more 
affordable  and  readily  available.  Pediatric  APL 
protocols  are  also  modified  to  include  cytarabine 
during consolidation therapy. The median age of APL 
patients in the complete series (adults and pediatrics) 
was 29 years. Although our population age is slightly 
younger than what is reported in various prospective 
trials  (about  37-40  years),
8,11 it  is  similar  to  the 
recorded  median  age  (30  years)  in  another 
retrospective study by the Tunisian group.
12 While the 
predominance of the intermediate risk group is in line 
with various prospective studies (~50%),
8,11 there was a 
slightly higher proportion of high risk patients (35%) in 
the  present  series  compared  to  most  other  studies 
which  report  a  frequency  of  25%  for  this  APL 
subgroup.
8,11 This  figure  was  similar  to  two 
retrospective series by the Tunisian and the Brazilian 
group, who reported 35% and 37%, respectively.
12,13
The overall mortality was 13% and bleeding (67%)




Total deaths 9 13.43
Causes of death
- Early before induction 5 7.46
Bleeding  5
- Induction Mortality 3 4.47
Bleeding  1
Febrile neutropenia  2
- Consolidation mortality 1 1.49
Febrile neutropenia  1
was the main cause of death in this series.  Early death 
was the major cause of mortality (12%) and most of 
these patients (7.5%) died at diagnosis before induction 
therapy. The reported early death rate in this series is in 
line  with  what  is  reported  in  two  recent  studies  of 
population  based  registries,  the  Swedish  adult  acute 
leukemia  registry  and  the  US  SEER.  Both  studies 
reported a high early mortality rate in APL patients of 
arround 30% and 17%, respectively.
14,15 In the former 
study, the main cause of early death was hemorrhage 
(41%) that occurred within 14 days. Most of  the cases 
also died even before initiation of therapy.
14
The rationale for avoiding Ara-C in the PETHEMA 
trial  LPA  99  was  to  reduce  death  in  CR  without 
increasing  the  incidence  of  relapse.  In  fact  in  the 
presented series, one patient died during consolidation 
representing 1.5%  of overall  mortality  similar  to  the 
observed rate in the PETHEMA LPA 99 trial (1.3%).
9
Again, only two patients relapsed and are still alive and 
in  CR  after  treatment  with  the  same  Cairo-NCI 
induction  protocol.  The  rate  of  differentiation 
syndrome  (11%)  was  similar  to  that  in  other 
reports.
8,9,11 Despite  the  limited  resources  that 
mandated modifications of the original LPA99 protocol 
we were able to document a CR rate (100% CRm in 
evaluable patients) and OS similar to those reported in 
the PETHEMA LPA99 protocol (>85%).
9,11
We  recognize  the  limitations  of  our  results  since 
this is a retrospective report of a relatively small series 
of  patients  observed  and  treated  in  a  single  center. 
Therefore,  these  results  need  to  be  confirmed 
prospectively in  larger  series.  However,  the  CR rate 
and OS are encouraging and suggest that despite the 
limited  resources  available  in  developing  countries 
APL patients can still achieve outcomes comparable to 
international standards. 
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